Enliven Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 46
- Market Cap
- $1B
- Introduction
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headqu...
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 275
- Registration Number
- NCT06328738
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 198
- Registration Number
- NCT05650879
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus - PPDS, Aurora, Colorado, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Enliven Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT05304377
- Locations
- 🇪🇸
Hospital Del Mar, Barcelona, Spain
🇪🇸Hospital Universitario de Gran Canaria Dr. Negrin, Servicio Canario e Salud (SCS), Las Palmas De Gran Canaria, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain